SAN FRANCISCO--(BUSINESS WIRE)--Dec. 12, 2016--
Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health
company focused on developing and commercializing first-in-class
gastrointestinal products for companion and production animals, foals,
and high value horses, today announced that it has signed a distribution
agreement (the “Agreement”) with Henry Schein, Inc., the world’s largest
provider of health care products and services to office-based dental,
animal health and medical practitioners, for exclusive distribution of
Jaguar’s Neonorm™ Foal product to all segments of the U.S.
equine market.
Henry Schein’s animal health business, Dublin, Ohio-based Henry Schein
Animal Health, employs approximately 900 team members and had 2015 net
sales of $2.9 billion. With 12 strategically positioned,
state-of-the-art distribution facilities and 10 inside sales centers
nationwide, we believe Henry Schein Animal Health is positioned to bring
a broad selection of veterinary products and strategic business
solutions to more than 26,000 veterinary professionals nationwide.
Neonorm™ Foal is a natural, clinically-tested, non-drug
product designed for use as an anti-diarrheal in foals. The product,
which acts locally in the gut and is minimally absorbed systemically,
contains a proprietary, standardized botanical extract derived from the Croton
lechleri tree, which is sustainably harvested.
Neonorm™ Foal was featured at Henry Schein’s booth at the
American Association of Equine Practitioners (AAEP) Annual Convention in
Orlando from December 4th – 6th, 2016.
“We are very excited to have the support of one the world’s leading
companion animal health distribution companies in our effort to drive
sales of Neonorm™ Foal throughout the U.S. equine market,”
stated Lisa Conte, Jaguar’s president and CEO. “We look forward to
leveraging the great exposure that Neonorm™ Foal received at
last week’s AAEP conference and collaborating closely with Henry
Schein’s team of sales personnel dedicated to the equine space.”
Diarrhea is one of the most common clinical complaints in foals,
especially within the first 30 days of life, and to the Company’s
knowledge there are currently no commercially available products with
anti-secretory properties for foals. The crippling effects of
dehydration that often occur as a result of secretory diarrhea in foals
can manifest quickly, precipitate adverse health effects and result in
death.
Foaling season in the northern hemisphere takes place from January to
July. Jaguar estimates that approximately 300,000 to 360,000 foals are
born in the U.S. each year based on data from the American Horse Council
that states that there are currently 9.2 million horses in the U.S., a
population that includes 844,531 race horses, more than 2.7 million show
horses, and more than 3.9 million recreational horses. Data from the
Food and Agriculture Organization of the United Nations indicate that
there were approximately 5.7 million horses in Europe in 2013 and nearly
60 million horses in 2013 worldwide.
The Agreement became effective on December 9, 2016, and, subject to
provisions specified in the Agreement, shall continue in force for an
initial period of one year. Thereafter, unless either party notifies the
other of its intent not to renew the term of the Agreement at least 30
days prior to the end of the then current term, the term shall be
automatically renewed upon expiration for successive renewal terms of
one year.
About Jaguar Animal Health, Inc.
Jaguar Animal Health, Inc. is an animal health company focused on
developing and commercializing first-in-class gastrointestinal products
for companion and production animals, foals, and high value horses.
Canalevia™ is Jaguar’s lead prescription drug product
candidate, intended for the treatment of various forms of diarrhea in
dogs. Equilevia™ (formerly referred to as SB-300) is Jaguar’s
prescription drug product candidate for the treatment of
gastrointestinal ulcers in horses. Canalevia™ and Equilevia™
contain ingredients isolated and purified from the Croton lechleri
tree, which is sustainably harvested. Neonorm™ Calf and
Neonorm™ Foal are the Company’s lead non-prescription
products. Neonorm™ is a standardized botanical extract
derived from the Croton lechleri tree. Canalevia™ and
Neonorm™ are distinct products that act at the same last step
in a physiological pathway generally present in mammals. Jaguar has nine
active investigational new animal drug applications, or INADs, filed
with the FDA and intends to develop species-specific formulations of
Neonorm™ in six additional target species, formulations of
Equilevia™ in horses, and Canalevia™ for cats and
dogs.
For more information, please visit www.jaguaranimalhealth.com.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking
statements” within the meaning of section 27A of the Securities Act of
1933 and section 21E of the Securities Exchange Act of 1934. These
include statements regarding the belief that Henry Schein Animal Health
is positioned to bring a broad selection of veterinary products and
strategic business solutions to more than 26,000 veterinary
professionals nationwide, planned efforts by Jaguar and Henry Schein to
drive sales of Neonorm™ Foal throughout the U.S. equine
market, the Company’s plans to leverage the exposure that Neonorm™
Foal received at the AAEP conference, and Jaguar’s intention to develop
species-specific formulations of Neonorm™ in six additional
target species, formulations of Equilevia™ in horses, and
Canalevia™ for cats and dogs. In some cases, you can identify
forward-looking statements by terms such as “may,” “will,” “should,”
“expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,”
“project,” “contemplate,” “believe,” “estimate,” “predict,” “potential”
or “continue” or the negative of these terms or other similar
expressions. The forward-looking statements in this release are only
predictions. Jaguar has based these forward-looking statements largely
on its current expectations and projections about future events. These
forward-looking statements speak only as of the date of this release and
are subject to a number of risks, uncertainties and assumptions, some of
which cannot be predicted or quantified and some of which are beyond
Jaguar’s control. Except as required by applicable law, Jaguar does not
plan to publicly update or revise any forward-looking statements
contained herein, whether as a result of any new information, future
events, changed circumstances or otherwise.
Jaguar-JAGX
View source version on businesswire.com: http://www.businesswire.com/news/home/20161212005633/en/
Source: Jaguar Animal Health, Inc.
KCSA Strategic Communications
Garth Russell, 212-896-1250
grussell@kcsa.com
